Mammalian target of rapamycin and head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a major global cause of cancer mortality.
• Tumorigenesis in HNSCC involves complex, stepwise malignant progression.
• The mammalian target of rapamycin (mTOR) pathway is implicated in critical aspects of tumor development.

Purpose of the Study:

• To review the pathogenesis of HNSCC.
• To elucidate the role of the mTOR pathway in HNSCC.
• To discuss the therapeutic potential of mTOR inhibitors in HNSCC management.

Main Methods:

• Literature review of HNSCC pathogenesis.
• Analysis of the mTOR signaling pathway in cancer.
• Review of studies on mTOR inhibitors in HNSCC models.

Main Results:

• mTOR signaling is crucial for HNSCC tumor development, invasion, metastasis, and angiogenesis.
• mTOR activity correlates with local recurrence and patient survival.
• mTOR inhibitors demonstrate efficacy in suppressing tumor growth in preclinical HNSCC models.
• mTOR inhibition sensitizes HNSCC to radiation, chemotherapy, and targeted therapies.

Conclusions:

• The mTOR pathway is a key driver in HNSCC progression and a potential biomarker for personalized therapy.
• Targeting the mTOR pathway with inhibitors offers a promising therapeutic strategy for HNSCC.
• mTOR inhibitors enhance the effectiveness of standard HNSCC treatments, including radiation and chemotherapy.